Larvol Veri

BIOMARKER:

DNMT3A mutation

Entrez ID:

1788

Related biomarkers:

Expression

Mutation

CNA

‹

›

DNMT3A mutation DNMT3A mutation	Acute Myelogenous Leukemia AML	venetoclax + midostaurin Resistant: C3 – Early Trials venetoclax + midostaurin Resistant : C3
DNMT3A mutation DNMT3A mutation	Myelodysplastic Syndrome MDS	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3
DNMT3A mutation DNMT3A mutation	Acute Myelogenous Leukemia AML	cytarabine + idarubicin Resistant: C3 – Early Trials cytarabine + idarubicin Resistant : C3
DNMT3A mutation DNMT3A mutation	Acute Myelogenous Leukemia AML	venetoclax Sensitive: C3 – Early Trials venetoclax Sensitive : C3
DNMT3A mutation DNMT3A mutation	Acute Myelogenous Leukemia AML	venetoclax + gilteritinib Resistant: C3 – Early Trials venetoclax + gilteritinib Resistant : C3
DNMT3A mutation DNMT3A mutation	Acute Myelogenous Leukemia AML	venetoclax + sorafenib Resistant: C3 – Early Trials venetoclax + sorafenib Resistant : C3
DNMT3A mutation DNMT3A mutation	Myelodysplastic Syndrome MDS	azacitidine Resistant: C3 – Early Trials azacitidine Resistant : C3
DNMT3A mutation DNMT3A mutation	Myelodysplastic Syndrome MDS	decitabine Resistant: C3 – Early Trials decitabine Resistant : C3
DNMT3A mutation DNMT3A mutation	Acute Myelogenous Leukemia AML	azacitidine Resistant: C3 – Early Trials azacitidine Resistant : C3
DNMT3A mutation DNMT3A mutation	Acute Myelogenous Leukemia AML	quizartinib Sensitive: C3 – Early Trials quizartinib Sensitive : C3
DNMT3A mutation DNMT3A mutation	Chronic Myeloid Leukemia CML	YD312 Resistant: C3 – Early Trials YD312 Resistant : C3
DNMT3A mutation DNMT3A mutation	Acute Myelogenous Leukemia AML	decitabine/cedazuridine Sensitive: C3 – Early Trials decitabine/cedazuridine Sensitive : C3
DNMT3A mutation DNMT3A mutation	Colorectal Cancer CRC	sintilimab + fruquintinib Resistant: C3 – Early Trials sintilimab + fruquintinib Resistant : C3
DNMT3A mutation DNMT3A mutation	T Cell Non-Hodgkin Lymphoma T Cell Non-Hodgkin Lymphoma	lenalidomide Resistant: C3 – Early Trials lenalidomide Resistant : C3
DNMT3A mutation DNMT3A mutation	Acute Myelogenous Leukemia AML	EPZ-5676 Sensitive: D – Preclinical EPZ-5676 Sensitive : D
DNMT3A mutation DNMT3A mutation	Acute Myelogenous Leukemia AML	ABBV-744 Sensitive: D – Preclinical ABBV-744 Sensitive : D
DNMT3A mutation DNMT3A mutation	Melanoma Melanoma	TdCyd Sensitive: D – Preclinical TdCyd Sensitive : D
DNMT3A mutation DNMT3A mutation	Breast Cancer Breast Cancer	TdCyd Sensitive: D – Preclinical TdCyd Sensitive : D
DNMT3A mutation DNMT3A mutation	Renal Cell Carcinoma RCC	TdCyd Sensitive: D – Preclinical TdCyd Sensitive : D

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES